shareholder value. On the heels of significant shareholder discontent, John Johnson, former CEO and chairman at Savient Pharmaceuticals , replaced Mitchell Gold as chief executive in 2012 and also took over as chairman of the board. The management
Oct 14 (Reuters) - U.S. biotech firm Savient Pharmaceuticals Inc filed for Chapter 11 bankruptcy protection in a Delaware court on Monday and said it has agreed to sell most of its assets to Sloan...
Savient SVNT (rating: CC) reported another quarter of disappointing results, and we plan to drop equity and credit coverage of the name
Despite numerous setbacks and poor execution, Savient still has a strong product.
Savient Pharmaceuticals SVNT reported third-quarter results that were largely in line with our expectations. Krystexxa remains on the slow-but-steady
Savient SVNT reported second-quarter Krystexxa sales that were largely in line with expectations and we do not plan to change our fair value
(Reuters) - Savient Pharmaceuticals Inc said it would cut about 35 percent of its workforce and named a new chief executive as it struggles to stay afloat amid weak sales of its chronic gout drug...
Savient Pharmaceuticals SVNT announced that Louis Ferrari, executive vice president and president of North American commercial operations, has been appointed
(Reuters) - Savient Pharmaceuticals Inc posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent.
Savient SVNT reported weaker-than-expected first-quarter Krystexxa sales, and we plan to lower our fair value estimate to $1.50 from